To the Editor: Dr Montalescot and colleagues
analyzed 6 trials of early vs late Gp IIb/IIIa inhibitors and concluded that
early administration confers significant angiographic and clinical benefit.1 I have concerns about whether this interpretation
is warranted.

First, it appears that studies using electrocardiographic (ST segment
resolution) end points and angiographic (Thrombolysis in Myocardial Infarction
[TIMI] flow) end points were combined. It is possible that if the study by
Zorman et al2 (which used electrocardiographic
criteria as a primary end point) had been excluded from the analysis, the
authors would not have found significant benefit.